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March 2006640 Abstractscontrol. Detailed analysis of the data indicates the drug had no effect on leg
revascularization or need for amputation. There is beginning to be accumu-
lated evidence that systemic markers of inflammation are perhaps more
important in predicting coronary events than events secondary to peripheral
vascular disease. If this proves to be true, then the results of this study would
make sense in that one of the primary effects of this drug is to lower markers
of systemic inflammation.
Increased Platelet Count and Leukocyte-Platelet Complex Formation
in Acute Symptomatic Compared With Asymptomatic Severe Carotid
Stenosis
McCabe DJH, Harrison P, Mackie IJ, et al. Journal Neurology, Neurosur-
gery, Psychiatry 2005;76:1249-54.
Conclusion: The mechanism of symptomatic carotid stenosis predis-
posing to stroke may in part be related to increased platelet count and
leukocyte-platelet complex formation.
Summary: The authors sought to determine why risk of stroke is
significantly higher in patients with recently symptomatic carotid stenosis
versus those with asymptomatic carotid stenosis. They hypothesized that
excess platelet activation may contribute to this difference. Patients were
tested with whole blood flow cytometry to measure platelet surface expres-
sion of CD62P, CD63, and PAC1 binding and percentage of leukocyte
platelet complexes. Three groups of patients were evaluated. Those who had
acute symptoms in the previous 0-21 days (n  19), convalescent patients
who had symptoms from 79-365 days in the past (n 16), and patients with
asymptomatic carotid stenosis (n  16). Most patients were on aspirin,
although alternative anti-thrombotic therapies were used more often in the
patients with symptomatic carotid stenosis.
In patients with acute and convalescent symptomatic carotid stenosis,
the mean platelet count was higher than in patients with asymptomatic
carotid stenosis. There were no differences between CD62P, CD63, or
PAC1 binding between the three groups. Patients with acute symptomatic
carotid stenosis had higher median percentages of neutrophil-platelet,
monocyte-platelet, and lymphocyte-platelet complexes (p, 0.004, 0.046,
and 0.02 respectively). In patients on only aspirin therapy, neutrophil
platelet and monocyte platelet complexes were higher in those with acute
symptomatic plaques than in patients with asymptomatic plaques (P 
0.03). In patients with convalescent symptomatic carotid stenosis, median
percentages of leukocyte platelet complexes in the symptomatic group were
similar to those found in the asymptomatic group.
Comment: The severity of carotid stenosis appears to be reasonably
well correlated with symptoms in symptomatic patients and perhaps mod-
erately well correlated in asymptomatic patients. Nevertheless, most patients
with even severe carotid stenosis do not have strokes. Much research has
focused on the plaque as a discerning factor for risk of stroke in patients with
carotid stenosis. Research such as this presented here is also highly interest-
ing in that it suggests the risk of stroke is going to be effected not only by
stenosis and plaque composition, but also by blood rheology.
Association of a Functional Polymorphism in the Clopidogrel Target
Receptor Gene P2Y12 and the Risk for Ischemic Cerebrovascular
Events in Patients With Peripheral Arterial Disease
Ziegler S, Schillinger M, Funk M, et al. Stroke 2005;36:1394-9.
Conclusion: There is a variable response to Clopidogrel in patients
with peripheral arterial disease (PAD). This may lead to an increase in
cerebrovascular events.
Summary: Clopidogrel is an antiplatelet agent with considerable vari-
ability in antiplatelet affects. Clopidogrel resistance has been shown to be
associated with recurrent cardiovascular events in patients with acute coro-
nary syndromes. The authors assessed the effect of gene sequence variations
in P2Y12 with occurrence of neurologic adverse events in patients with
symptomatic PAD who were treated with clopidogrel. Patients who had
symptomatic PAD as manifested by intermittent claudication, critical limb
ischemia, or a history of surgical or endovascular lower limb revasculariza-
tion were eligible for the study. There were 137 patients who were under-
going antiplatelet therapy with clopidogrel and 336 who were treated with
aspirin. These patients were followed for occurrence of neurologic events
(ischemic stroke and/or carotid revascularization). Polymerase chain reac-
tion was used to determine the prevalence of 2 polymorphisms of the P2Y12
gene, 34CT and 52GT.
Mutated, heterozygous and wild type alleles for the 34 CT polymor-
phism were 9% (n  40), 44% (n  210), and 47% (n  223). Genotype
frequencies for the mutated, heterozygous and wild type alleles for the
52GT polymorphism were 4% (n  17), 27% (n  127), and 70% (n 
329). Median followup was 21 months. Eight percent of the patients had a
neurologic event during followup. Patients treated with aspirin showed no
association between neurologic events and either the 34CT or 52GT
polymorphisms. However, clopidogrel patients with at least one 34T allele
had a 4.02 times increased risk for neurologic events compared with carriers
of only 34C alleles (95% confidence interval, 1.08 to 14.9).Comment: Like with aspirin, there appears to be a significant inter-
individual variability in the antiplatelet effect of clopidogrel. This study
suggests identification of the 34CT polymorphismmay serve as a predictor
of the efficacy of clopidogrel to prevent neurologic events in patients with
PAD. Patients with neurologic events on antiplatelet therapy should prob-
ably be assessed for either aspirin or clopidogrel resistance, and their anti-
platelet agent adjusted accordingly.
Statins are Associated with Better Outcomes After Carotid Endarter-
ectomy in Symptomatic Patients
Kennedy J, Kuan H, Buchan AM, et al. Stroke 2005;36:2073-6.
Conclusion: Statin therapy appears to have a protective effect in
symptomatic patients undergoing carotid endarterectomy.
Summary: Pleiotropic effects of statins are widely appreciated. Statins
are associated with a reduction in mortality in non cardiac surgery. This
study determined the effect of statin use at the time of hospital admission in
patients undergoing carotid endarterectomy. The authors sought to deter-
mine whether statin use at the time of hospital admission in patients
undergoing carotid endarterectomy was associated with a reduction of
in-hospital adverse outcomes. All carotid endarterectomy cases were identi-
fied in four western Canadian provinces from January 2000 to December
2001. Charts were abstracted for data describing patient characteristics,
surgical indication for endarterectomy, statin treatment, and in-hospital
outcomes with respect to death, ischemic stroke, as well as cardiac outcomes.
There were 3,360 patients included in the data base. Logistic regression
analysis was used to compare outcomes of patients on statins versus those not
on statins and to account for differences in patient characteristics. Propensity
score analysis was used to account for factors that may influence patient
treatment with statins.
At the time of hospital admission, 815 of 2,031 symptomatic patients
and 665 of 1,252 asymptomatic patients were on a statin medication.
Symptomatic patients on statins had reduced in-hospital mortality and
in-hospital ischemic stroke and death rates. There was no difference in
in-hospital cardiac outcomes. (Adjusted odd ratios 0.25 {CI, 0.07 to 0.90},
0.55 {CI, 0.32 to 0.95}, 0.87 {CI, 0.49 to 1.54}, respectively). Improve-
ment in outcome of symptomatic patients was robust when tested with
propensity score analysis. The association between outcomes and statin use
was not seen in asymptomatic patients.
Comment:The study adds to the growing impression that statins improve
perioperative outcomes in patients undergoing vascular surgery. The lack of
effect of statins in the asymptomatic patients undergoing carotid endarterec-
tomy may be the result of an inability to detect the statin effect due to the low
frequency of adverse events in the asymptomatic patients. Since this was not a
randomized study, statins, however, may just be serving as a marker of overall
better perioperative care. Results of this observational study and others like it
will need to be confirmed in large multi-center randomized trials specifically
addressing perioperative use of statins to improve operative outcomes.
Relationship Between HbA1c Level and Peripheral Arterial Disease
Munter P, Wildman RP, Reynolds K, et al. Diabetes Care 2005;28:1981-7.
Conclusion: There is an association between higher levels of hemoglo-
bin A1c and peripheral arterial disease, even in patients without diabetes.
Summary: Glucose control is felt to be important in the development
of peripheral arterial disease (PAD) in patients with diabetes. Glucose
control may also be important in the development of PAD in patients
without diabetes. The authors sought to evaluate hemoglobin A1c levels in
patients with and without diabetes and to compare these levels with preva-
lence of PAD.
This was a cross sectional study utilizing 4,526 participants in the
National Health and Nutrition Examination Survey, 1999-2002. Partici-
pants were all40 years of age. PAD was defined as the presence of an ankle
brachial index (ABI) 0.9 (n  327).
In patients without diabetes, age standardized prevalence of PAD was
3.1%, 4.8%, 4.7%, and 6.4% for subjects with a hemoglobin A1c 5.3%,
5.3-5.4%, 5.5-5.6%, and 5.7-6.0%, respectively (p-trend less than 0.001). In
patients with diabetes, peripheral arterial disease prevalence was 7.5% and
8.8% with respect to hemoglobin A1c levels 7% and 7%. Using multi-
variable analysis adjustments in comparison with non diabetic subjects, with
hemoglobin A1c less than 5.3%, the odds ratio (95% confidence intervals) of
PAD for diabetic subjects with hemoglobin A1c 5.3-5.4%, 5.5-5.6%, and
5.7-6.0% was 1.41 (0.85-2.32), 1.39 (0.70-2.75), and 1.57 (1.02-2.47)
respectively. The odds ratios for peripheral arterial disease in diabetic partic-
ipants with hemoglobin A1c levels 7% versus those 7% were 2.33 (1.15-
4.70), and 2.74 (1.25-.02) respectively.
Comment: The data suggests higher levels of hemoglobin A1c in
patients without diabetes may serve as a marker for increased risk of sub-
clinical cardiovascular disease. It may be that it’s not so much diabetes but
glucose control that contributes to the risk of atherosclerosis. Perhaps
diabetes merely serves as one end of the spectrum of the adverse effects of
increased glucose levels on atherosclerosis.
